Essentra (ESNT) Insider Buys £800 in Stock

Essentra (LON:ESNT) insider Paul Forman acquired 20,000 shares of the business’s stock in a transaction on Friday, April 6th. The shares were purchased at an average cost of GBX 4 ($0.06) per share, for a total transaction of £800 ($1,122.96).

Paul Forman also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Friday, March 16th, Paul Forman acquired 20,000 shares of Essentra stock. The shares were purchased at an average cost of GBX 461 ($6.47) per share, for a total transaction of £92,200 ($129,421.67).

ESNT stock opened at GBX 424.40 ($5.96) on Friday. Essentra has a 52-week low of GBX 438.02 ($6.15) and a 52-week high of GBX 588.50 ($8.26).

Essentra (LON:ESNT) last released its earnings results on Friday, March 2nd. The company reported GBX 22.10 ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of GBX 22.80 ($0.32) by GBX (0.70) (($0.01)). Essentra had a net margin of 2.91% and a return on equity of 4.67%. The business had revenue of GBX 102.73 billion for the quarter.

The company also recently disclosed a dividend, which will be paid on Tuesday, May 1st. Investors of record on Thursday, March 15th will be issued a GBX 14.40 ($0.20) dividend. This is a positive change from Essentra’s previous dividend of $6.30. This represents a yield of 2.93%. The ex-dividend date of this dividend is Thursday, March 15th.

Several equities analysts have recently issued reports on the stock. Peel Hunt upgraded shares of Essentra to a “buy” rating and lowered their target price for the company from GBX 585 ($8.21) to GBX 550 ($7.72) in a report on Friday, March 2nd. Deutsche Bank reiterated a “buy” rating on shares of Essentra in a report on Friday. Numis Securities reiterated a “hold” rating and set a GBX 500 ($7.02) target price on shares of Essentra in a report on Monday, March 5th. Finally, Jefferies Group reiterated a “hold” rating and set a GBX 510 ($7.16) target price on shares of Essentra in a report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of GBX 520 ($7.30).

TRADEMARK VIOLATION WARNING: “Essentra (ESNT) Insider Buys £800 in Stock” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3336710/essentra-esnt-insider-buys-800-in-stock.html.

Essentra Company Profile

Essentra plc manufactures and sells specialist plastic, fiber, foam, and packaging products worldwide. It operates through four divisions: Component, Packaging, Filter Products, and Specialist Components. The Component division offers plastic injection molded, vinyl dip-molded, and metal items for equipment manufacturing, automotive, fabrication, electronics, and construction industries; and component solutions for protection and finishing purposes.

Insider Buying and Selling by Quarter for Essentra (LON:ESNT)

Receive News & Ratings for Essentra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Essentra and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Clean Energy Fuels  Given Daily Media Impact Rating of -0.02
Clean Energy Fuels Given Daily Media Impact Rating of -0.02
Somewhat Favorable News Coverage Somewhat Unlikely to Affect Monroe Bank & Trust  Share Price
Somewhat Favorable News Coverage Somewhat Unlikely to Affect Monroe Bank & Trust Share Price
Northrim BanCorp  Receiving Positive Media Coverage, Analysis Shows
Northrim BanCorp Receiving Positive Media Coverage, Analysis Shows
ArQule  Getting Somewhat Favorable Press Coverage, Accern Reports
ArQule Getting Somewhat Favorable Press Coverage, Accern Reports
Franko Market Capitalization Tops $115,130.00
Franko Market Capitalization Tops $115,130.00
Pluristem Therapeutics  PT Set at $3.00 by Maxim Group
Pluristem Therapeutics PT Set at $3.00 by Maxim Group


© 2006-2018 Ticker Report. Google+.